Index by Author

December 2007; 7 (6)
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z

B

  1. Blakely, Randy D.

    • Bound to Be Different: Neurotransmitter Transporters Meet Their Bacterial Cousins Mol Interv December 2007 7:306-309; doi:10.1124/mi.7.6.4

  2. Blumberg, Peter M.

    • Lighting a Backfire to Quench the Blaze: A Combined Drug Approach Targeting the Vanilloid Receptor TRPV1 Mol Interv December 2007 7:310-312; doi:10.1124/mi.7.6.5

C

  1. Chen, Alice

    • Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol Interv December 2007 7:325-334; doi:10.1124/mi.7.6.9

  2. Collins, Jerry

    • Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol Interv December 2007 7:325-334; doi:10.1124/mi.7.6.9

D

  1. Doroshow, James H.

    • Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol Interv December 2007 7:325-334; doi:10.1124/mi.7.6.9

G

  1. Gutierrez, Martin

    • Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol Interv December 2007 7:325-334; doi:10.1124/mi.7.6.9

H

  1. Helman, Lee

    • Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol Interv December 2007 7:325-334; doi:10.1124/mi.7.6.9

  2. Henry, L. Keith

    • Bound to Be Different: Neurotransmitter Transporters Meet Their Bacterial Cousins Mol Interv December 2007 7:306-309; doi:10.1124/mi.7.6.4

  3. Hollingshead, Melinda

    • Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol Interv December 2007 7:325-334; doi:10.1124/mi.7.6.9

  4. Houston, Dayle

J

  1. Ji, Jay

    • Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol Interv December 2007 7:325-334; doi:10.1124/mi.7.6.9

K

  1. Kinders, Robert

    • Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol Interv December 2007 7:325-334; doi:10.1124/mi.7.6.9

  2. Kummar, Shivaani

    • Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol Interv December 2007 7:325-334; doi:10.1124/mi.7.6.9

M

  1. Meiler, Jens

    • Bound to Be Different: Neurotransmitter Transporters Meet Their Bacterial Cousins Mol Interv December 2007 7:306-309; doi:10.1124/mi.7.6.4

  2. Murgo, Anthony J.

    • Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol Interv December 2007 7:325-334; doi:10.1124/mi.7.6.9

P

  1. Parascandola, John

  2. Parchment, Ralph E.

    • Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol Interv December 2007 7:325-334; doi:10.1124/mi.7.6.9

  3. Pickeral, Oxana

    • Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol Interv December 2007 7:325-334; doi:10.1124/mi.7.6.9

R

  1. Rubinstein, Larry

    • Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol Interv December 2007 7:325-334; doi:10.1124/mi.7.6.9

S

  1. Simpson, Mel

    • Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol Interv December 2007 7:325-334; doi:10.1124/mi.7.6.9

  2. Steinberg, Seth M.

    • Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol Interv December 2007 7:325-334; doi:10.1124/mi.7.6.9

T

  1. Tomaszewski, Joseph E.

    • Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol Interv December 2007 7:325-334; doi:10.1124/mi.7.6.9

  2. Townsend, Danyelle M.

    • S-Glutathionylation: Indicator of Cell Stress and Regulator of the Unfolded Protein Response Mol Interv December 2007 7:313-324; doi:10.1124/mi.7.6.7

W

  1. Wiltrout, Robert

    • Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol Interv December 2007 7:325-334; doi:10.1124/mi.7.6.9

Y

  1. Yang, Sherry

    • Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol Interv December 2007 7:325-334; doi:10.1124/mi.7.6.9

Current Issue

  1. April 2011, 11 (2)
  1. Current Issue
  1. Alert me to new issues of MI
Society Logo HighWire Press Logo CLOCKSS logo